| abstract |
The present invention provides a method of inducing lymphangiogenesis in the brain or central nervous system of a subject, wherein an effective amount of a lymphangiogenesis-inducing agent is administered. The present invention provides a method of inducing lymphangiogenesis in a tumor of the brain or central nervous system of a subject, wherein an effective amount of a lymphangiogenesis-inducing agent is administered. The present invention also provides a method of treating cancer of the brain or central nervous system, wherein an effective amount of a lymphangiogenesis-inducing agent is administered. An example of such a lymphangiogenesis-inducing agent is VEGFC. The lymphangiogenesis-inducing agent may be in the form of a protein or a polynucleotide encoding a protein, such as mRNA or AAV. The lymphangiogenesis-inducing agent can be administered to the cistern or directly into the lymphatic system. Immunotherapeutic agents, such as checkpoint inhibitors, can also be administered. |